This protective effect against infections has been observed also for other type 2 immune diseases when treated with biologics targeting the IL-4R complex, such as the anti-IL-13 antibody Lebrikizumab in asthma and AD (118, 119) and the IL-4Rα-blocking agent Pitrakinra in asthma (120). The gene discussed is IL13; the disease is asthma.